The Pharmaceutical Index: 2013 Worldwide NCEs, 1st Edition (Hardback) book cover

The Pharmaceutical Index

2013 Worldwide NCEs, 1st Edition

Edited by Pharmacodia (Beijing) Co.,Ltd.

CRC Press

502 pages

Purchasing Options:$ = USD
Hardback: 9787506778787
pub: 2016-11-28
SAVE ~$87.00
$435.00
$348.00
x

FREE Standard Shipping!

Description

An ideal drug candidate should possess good pharmacological activity, absorption, distribution, metabolism, excretion and toxicity properties. Historically, there are around 6,000 drugs being used in humans and approximately 3,000 still in clinical use, not including herbal medicines. This Pharmaceutical Index series focuses on the profiles of 500 pharmaceutically marketed products from the past two decades. Professor Dr. K. Barry Sharpless is Honorary Editor-in-Chief of this first Index by Pharmacodia. The volume includes 24 NCEs worldwide approved drugs in 2013. Pharmacodia plan to publish two further volumes which will feature 2014 NCEs (32 drugs) and 2015 NCEs (25 drugs).

Reviews

‘This new series of Pharmaceutical Indexes will be a boon in academia and the pharmaceutical industry, and provide, as well, a significant addition to the therapeutics discovery arsenal. It should also find a wide audience in government, and the business community.’

– K. Barry Sharpless, Nobel Prize Winner in Chemistry, 2001.

‘The most fruitful basis for the discovery of a new drug is to start with an old drug.’

– James W. Black, Nobel Prize Winner in Physiology or Medicine, 1998.

Table of Contents

Executive Summary

Chapter 1: Acotiamide Hydrochloride Hydrate

Chapter 2: Afatinib Dimaleate

Chapter 3: Canagliflozin Hemihydrate

Chapter 4: Cetilistat

Chapter 5: Cobicistat

Chapter 6: Dabrafenib Mesylate.

Chapter 7: Dimethyl Fumarate

Chapter 8: Dolutegravir Sodium

Chapter 9: Efinaconazole

Chapter 10: Elvitegravir

Chapter 11: Glycerol Phenylbutyrate

Chapter 12: Ibrutinib

Chapter 13: Istradefylline

Chapter 14: Levomilnacipran Hydrochloride

Chapter 15: Macitentan

Chapter 16: Olodaterol Hydrochloride

Chapter 17: Ospemifene

Chapter 18: Pomalidomide

Chapter 19: Riociguat

Chapter 20: Simeprevir Sodium

Chapter 21: Sofosbuvir

Chapter 22: Topiroxostat

Chapter 23: Trametinib Dimethyl Sulfoxide

Chapter 24: Vortioxetine Hydrobromide

Appendix I. Abbreviation

Appendix II. Worldwide Approved NCEs (2001-2014)

Subject Categories

BISAC Subject Codes/Headings:
MED071000
MEDICAL / Pharmacology
MED072000
MEDICAL / Pharmacy
SCI013000
SCIENCE / Chemistry / General